|Daily Range||$66.51 - $67.24|
|52-Week Range||$45.50 - $70.76|
|Dividend (Yield)||$1.96 (3.0%)|
Dividend Pay Date
|Average Daily Volume||7,010,606|
|Current FY EPS||$3.30|
AbbVie Inc. (ABBV) Description
AbbVie Inc. Website: http://www.abbvie.com/
News & Commentary
Gilead Sciences' slate of catalysts and a forward P/E of less than 10 make it intriguing.
Three Motley Fool contributors tell us which biotech stocks they think could make a big move next year.
Costly new drugs have driven pharma stock prices to all-time highs over the last two years. Here's why this trend might come to a screeching halt.
Hedge funds have been buying more and more of these three stocks in recent months.
Achillion Pharmaceuticals ACH-3102 helps cure hepatitis C patients more quickly than Gilead Sciences and AbbVie.
Gilead Sciences, Orexigen Therapeutics, and Prothena Corp. are all poised to have a huge 2015. Here's what investors need to know.